From the Department of Radiology, Université Paris Cité, Paris, France (M.R.); Department of Radiology, Hôpital Beaujon, APHP.Nord, Clichy, France (M.R.); Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Mass (V.C.); Departments of Medical Oncology (A.B.) and Internal Medicine (J.C.), University of California-San Diego, La Jolla, Calif; Department of Radiology, West China Hospital, Sichuan University, Chengdu, China (H.J.); Department of Radiology, Duke University Medical Center, Durham, NC (M.B.); and Department of Radiology, University of California-San Diego, 6206 Lakewood St, San Diego, CA 92122 (K.J.F.).
Radiology. 2023 May;307(3):e221429. doi: 10.1148/radiol.221429. Epub 2023 Apr 4.
The focus of hepatocellular carcinoma (HCC) research for many years has been on noninvasive diagnosis. Standardized systematic algorithms composed of combinations of precise features now serve as diagnostic imaging markers of HCC and constitute a major innovation for liver imaging. In clinical practice, the diagnosis of HCC is based primarily on imaging and secondarily on pathologic analysis if the imaging features are not specific. Whereas accurate diagnosis is essential, the next phase of innovation for HCC will likely encompass predictive and prognostic markers. HCC is a biologically heterogeneous malignancy because of complex molecular, pathologic, and patient-level factors that impact the outcomes of treatment. In recent years, there have been many advances in systemic therapy to augment and extend the existing large cache of local and regional options. However, the guideposts for treatment decisions are neither sophisticated nor individualized. This review provides an overview of prognosis in HCC from the patient to the imaging feature level with a focus on future directions toward more individualized treatment guidance.
多年来,肝细胞癌 (HCC) 的研究重点一直是非侵入性诊断。现在,由精确特征组合而成的标准化系统算法已成为 HCC 的诊断影像学标志物,是肝脏影像学的重大创新。在临床实践中,HCC 的诊断主要基于影像学,如果影像学特征不具有特异性,则其次依据病理分析。虽然准确诊断至关重要,但 HCC 下一个创新阶段可能包括预测和预后标志物。由于影响治疗结果的复杂分子、病理和患者水平因素,HCC 是一种生物学异质性恶性肿瘤。近年来,全身性治疗方面取得了许多进展,以增加和扩展现有的大量局部和区域治疗方案。然而,治疗决策的指导方针既不复杂也不个体化。本综述从患者到影像学特征层面概述了 HCC 的预后,并重点介绍了朝着更个体化治疗指导方向的未来发展。